A novel optically pure pyridazinone derivative was synthesized and identified as a nonprostanoid PGI2 agonist. It inhibited ADP-induced aggregation of human platelets with an IC50 value of 0.081 μM and has high oral bioavailability (56%) with a long half-life (4.3 h) in rats.
